Jose Gonzalez-Juanatey, ACC 2021 – Findings from the REALITY clinical trial
We were delighted to meet with Jose Gonzalez-Juanatey to discuss the REALITY clinical trial investigating one-year major cardiovascular events after restrictive Vs liberal blood transfusion strategy among patients with acute myocardial infarction and anemia: and the potential impact on future clinical practice.
- An overview of the REALITY clinical trial (00:06)
- What impact might these findings have on clinical practice? (05:34)
Speaker disclosures: Jose Gonzalez-Juanatey has received research grants from: Boehringer-Ingelheim, Novartis, Bayer, AstraZeneca, and been a speaker or consultant to: Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daichii-Sankyo, Ferrer International, Novo Nordisk, Novartis, Pfizer, Sanofi, Servier.
Support: Interview and filming supported by Touch Medical Media and conducted by Nicola Cartridge.
Filmed during a remote video call with Professor Jose Gonzalez-Juanatey as a highlight of ACC 2021, May 2021.
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!